Cytotoxicity Mediated by Autologous Antileukemia T-Cell Lines Generated From Bulk Cultures of Bone Marrow Stimulated With sCD40L
Patient . | E:T Ratio . | Cytotoxicity (% of specific lysis) . | ||||
---|---|---|---|---|---|---|
. | . | Leukemia . | CD40 Leukemia . | Autologous Nonmalignant . | Allogeneic CD40-B . | K562 . |
ALL-17 | 20:1 | 45% | 61% | 10% | 7% | <5% |
ALL-20 | 40:1 | 37% | 56% | ND | <5% | ND |
ALL-21 | 40:1 | 63% | 71% | 14% | 11% | 8% |
ALL-25 | 20:1 | 51% | 92% | ND | 38% | ND |
ALL-28 | 40:1 | 48% | 69% | <5% | <5% | <5% |
ALL-30 | — | — | — | — | — | — |
ALL-31 | 20:1 | 28% | 43% | ND | <5% | <5% |
ALL-33 | 30:1 | 55% | 76% | ND | <5% | 10% |
ALL-36 | — | — | — | — | — | — |
ALL-38 | — | — | — | — | — | — |
ALL-39 | — | — | — | — | — | — |
ALL-41 | 30:1 | 32% | 60% | ND | 9% | <5% |
CML-1 | 40:1 | 35% | 52% | <5% | <5% | <5% |
CML-2 | 30:1 | 40% | 44% | ND | <5% | ND |
CML-3 | — | — | — | — | — | — |
Patient . | E:T Ratio . | Cytotoxicity (% of specific lysis) . | ||||
---|---|---|---|---|---|---|
. | . | Leukemia . | CD40 Leukemia . | Autologous Nonmalignant . | Allogeneic CD40-B . | K562 . |
ALL-17 | 20:1 | 45% | 61% | 10% | 7% | <5% |
ALL-20 | 40:1 | 37% | 56% | ND | <5% | ND |
ALL-21 | 40:1 | 63% | 71% | 14% | 11% | 8% |
ALL-25 | 20:1 | 51% | 92% | ND | 38% | ND |
ALL-28 | 40:1 | 48% | 69% | <5% | <5% | <5% |
ALL-30 | — | — | — | — | — | — |
ALL-31 | 20:1 | 28% | 43% | ND | <5% | <5% |
ALL-33 | 30:1 | 55% | 76% | ND | <5% | 10% |
ALL-36 | — | — | — | — | — | — |
ALL-38 | — | — | — | — | — | — |
ALL-39 | — | — | — | — | — | — |
ALL-41 | 30:1 | 32% | 60% | ND | 9% | <5% |
CML-1 | 40:1 | 35% | 52% | <5% | <5% | <5% |
CML-2 | 30:1 | 40% | 44% | ND | <5% | ND |
CML-3 | — | — | — | — | — | — |
The autologous nonmalignant cells were non-T, non-B (majority MHC I+/MHC II+) or PHA blasts (majority MHC I+/MHC II+). The cytotoxic assay was performed as described in the Materials and Methods.
Abbreviations: E:T, effector to target; ND, not determined.